Dabigatran is an anticoagulant thrombin inhibitor marketed by Boehringer and marketed as Pradaxa. The Dabigatran’s product patent is granted in india (370/DEL/1998 granted as 225735). It is marketed as dabigatran etexilate mesylate. This mesylate salt form of dabigatran prodrug (etexilate) is protected by WO2003074056 and WO2005028468.
The ‘056 patent application is also granted in India as 231731 (2251/DELNP/2004) and the ‘468 application equivalent 924/DELNP/2006, is now rejected by IPO which covers polymorphic form of dabigatran etexilate mesylate
Decision is available at IPO site